CN109266667B - 靶向cd5的嵌合抗原受体及其应用 - Google Patents
靶向cd5的嵌合抗原受体及其应用 Download PDFInfo
- Publication number
- CN109266667B CN109266667B CN201811310765.XA CN201811310765A CN109266667B CN 109266667 B CN109266667 B CN 109266667B CN 201811310765 A CN201811310765 A CN 201811310765A CN 109266667 B CN109266667 B CN 109266667B
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- nucleic acid
- acid molecule
- chimeric antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811310765.XA CN109266667B (zh) | 2018-11-06 | 2018-11-06 | 靶向cd5的嵌合抗原受体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811310765.XA CN109266667B (zh) | 2018-11-06 | 2018-11-06 | 靶向cd5的嵌合抗原受体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109266667A CN109266667A (zh) | 2019-01-25 |
CN109266667B true CN109266667B (zh) | 2021-08-03 |
Family
ID=65192110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811310765.XA Active CN109266667B (zh) | 2018-11-06 | 2018-11-06 | 靶向cd5的嵌合抗原受体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109266667B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112979820B (zh) * | 2019-12-17 | 2022-06-17 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 靶向cd123的嵌合抗原受体及含有靶向cd123嵌合抗原受体的双靶点嵌合抗原受体 |
CN116568709A (zh) * | 2020-11-01 | 2023-08-08 | 南京驯鹿生物技术股份有限公司 | 靶向cd5的全人源抗体、全人源嵌合抗原受体(car)及其应用 |
US20240050568A1 (en) * | 2021-01-12 | 2024-02-15 | Nanjing IASO Biotechnology Co., Ltd. | Fully human single-domain tandem chimeric antigen receptor (car) targeting cd5, and use thereof |
CN112961248B (zh) * | 2021-02-22 | 2022-03-18 | 广州百暨基因科技有限公司 | 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用 |
WO2023011651A1 (zh) * | 2021-08-06 | 2023-02-09 | 上海驯鹿生物技术有限公司 | Cd5和cd7双靶点的全人源嵌合抗原受体(car)及其应用 |
CN117431217A (zh) * | 2022-07-12 | 2024-01-23 | 上海驯鹿生物技术有限公司 | 表达靶向cd5的嵌合抗原受体(car)的细胞及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107249602A (zh) * | 2015-02-27 | 2017-10-13 | 美商生物细胞基因治疗有限公司 | 靶向血液恶性肿瘤之嵌合抗原受体(car)、其组合物及使用方法 |
CN111247168A (zh) * | 2017-10-12 | 2020-06-05 | 美商生物细胞基因治疗有限公司 | 靶向多种抗原的复合嵌合抗原受体(cCAR)及其组成和使用方法 |
-
2018
- 2018-11-06 CN CN201811310765.XA patent/CN109266667B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107249602A (zh) * | 2015-02-27 | 2017-10-13 | 美商生物细胞基因治疗有限公司 | 靶向血液恶性肿瘤之嵌合抗原受体(car)、其组合物及使用方法 |
CN111247168A (zh) * | 2017-10-12 | 2020-06-05 | 美商生物细胞基因治疗有限公司 | 靶向多种抗原的复合嵌合抗原受体(cCAR)及其组成和使用方法 |
Also Published As
Publication number | Publication date |
---|---|
CN109266667A (zh) | 2019-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108715859B (zh) | 靶向cd22的嵌合抗原受体及其应用 | |
CN109266667B (zh) | 靶向cd5的嵌合抗原受体及其应用 | |
CN108276493B (zh) | 一种嵌合抗原受体及其应用 | |
KR20210019993A (ko) | Τ 세포 수용체 및 이를 발현하는 조작된 세포 | |
KR20190025855A (ko) | 개선된 입양 t-세포 요법 | |
CN114656569B (zh) | 包含nkg2d结构域的多特异性嵌合受体和其使用方法 | |
CN112979820B (zh) | 靶向cd123的嵌合抗原受体及含有靶向cd123嵌合抗原受体的双靶点嵌合抗原受体 | |
CN113248616B (zh) | 靶向gpc3的嵌合抗原受体及其用途 | |
CN110257338B (zh) | 嵌合细胞因子受体 | |
CN117802051A (zh) | 修饰的细胞及组合物 | |
CN113583139A (zh) | 一种嵌合受体及其应用 | |
CN115551893A (zh) | 靶向自然杀伤细胞的嵌合抗原受体(car) | |
WO2020019983A1 (zh) | 一种用于治疗肿瘤的基因工程细胞 | |
CN108251442B (zh) | Flt3嵌合抗原受体及其应用 | |
CN114591444A (zh) | 一种基于cd7的人源化嵌合抗原受体及其应用 | |
CN112442508B (zh) | 靶向cd22和cd19的嵌合抗原受体及其应用 | |
CN112533943B (zh) | Il-13/il-4超级因子:免疫细胞靶向性构建体及其使用方法 | |
CN111826353B (zh) | 调节t细胞功能和反应的方法 | |
US20240000937A1 (en) | Methods and compositions of car-expressing natural killer cells with bispecific antigen-binding molecules as cancer therapeutic agents | |
CN113549155B (zh) | 同时靶向cd19和cd20的嵌合抗原受体及其应用 | |
CN114790462B (zh) | 靶向bcma的嵌合抗原受体及其应用 | |
CN116239692B (zh) | 分离的抗体、包含该抗体的car及其用途 | |
US20230019849A1 (en) | Method for Preparing CD7-Negative, CD3-Positive T Cells | |
CN117343191A (zh) | 分泌PD1和CTLA4双单域抗体的EGFRvⅢCAR-T细胞及其制备方法和应用 | |
EP4121518A1 (en) | Engineered cell compositions and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Jianxiang Inventor after: Wang Min Inventor after: Liu Qian Inventor after: Xu Yingqian Inventor after: Rao Qing Inventor after: Liao Xiaolong Inventor before: Wang Jianxiang Inventor before: Wang Min Inventor before: Liu Qian Inventor before: Xu Yingqian Inventor before: Rao Qing Inventor before: Liao Xiaolong |
|
CB03 | Change of inventor or designer information | ||
CB02 | Change of applicant information |
Address after: 300020 No. 288, Nanjing Road, Heping District, Tianjin Applicant after: Hematology Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) Address before: 300020 No. 288, Nanjing Road, Heping District, Tianjin Applicant before: Hematology Hospital of Chinese Academy of Medical Sciences (Institute of Hematology) |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |